Regarding maintenance therapy after allo-HCT, the single arm AMLSG 16-10 phase-II trial provided robust data about the safety and efficacy of midostaurin in younger (18–60 years) and older (60 to 70 years) patients with FLT3-ITD positive AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.